Novavax Initiates Pediatric Expansion for Phase 3 Clinical Trial of COVID-19 Vaccine

Published on :

Novavax Initiates Pediatric Expansion for Phase 3 Clinical Trial of COVID-19 Vaccine GAITHERSBURG, Md., May 3, 2021 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today [….]

Novavax Vaccine Could Generate $33 Billion in Revenue through 2027, Analyst Says

Published on :

Novavax is aiming to seek Emergency Use Authorization for its COVID-19 vaccine NVX-CoV2373 later this spring. If the U.S. Food and Drug Administration gives it the green light, the Maryland-based company could see revenue of approximately $1.8 billion in sales by the end of the year.

In Conversation: Dr. Vipin K. Garg, CEO of Altimmune

Published on :

Dr. Vipin Garg, Altimmune’s (ALT) CEO since 2018 and a biotech industry veteran, has successfully led the publicly-traded company through these turbulent pandemic waters. We recently caught up with Dr. Garg to discuss the pandemic, Altimmune’s deep product pipeline, his unique perspectives on the BioHealth Capital Region (BHCR), and the state of the U.S. supply chain and biotech manufacturing ecosystem.

Virginia Life Sciences Ecosystem Gets Boost from Essential Medicines-Focused Phlow, Civica Rx

Published on :

The ongoing COVID-19 pandemic greatly exposed a dearth of essential medications and significant vulnerabilities in the United States medical supply chain. Phlow Corporation aims to mitigate those weaknesses and manufacture essential generic medications at its Virginia manufacturing facility.

Novavax Initiates COVID-19 Vaccine Clinical Trial Crossover

Published on :

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the initiation of crossover arms in two ongoing clinical trials of NVX-CoV2373, the company’s COVID-19 vaccine candidate. Crossover ensures the administration of active vaccine to all participants in the trials and has begun for Novavax’ Phase 2b trial in South Africa and its pivotal Phase 3 trial in the United Kingdom.

Connected DMV, a Driving Force Behind Montgomery County’s New Global Pandemic Prevention and Biodefense Center

Published on :

Identifying gaps and bridging them—that’s what Connected DMV’s President and CEO Stu Solomon does best. And now he and his partners are turning their attention to one of the globe’s most important and challenging divides: Preparing for the next pandemic.